Amgen takes a swing at regenerative immunology with $721M acquisition of Rodeo Therapeutics

With blockbuster immunology meds Enbrel and Otezla already in the fold, Amgen has mostly stood pat on infusing new blood into its legacy pipeline. But that success won’t last forever, and Amgen is taking a far-looking bet on a private biotech forging a new pathway to treat immune system diseases.…

...

Click to view original post